ADCETRIS 50 mg(Brentuximab Vedotin) is an antibody-drug conjugate (ADC) comprised of an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).
Manufacturer : Seattle Genetics
Strengths available : 50mg
Storage : store at temperature between 2°C – 8°C
FDA Approved : US FDA Approved
Date of Approval : August 19th, 2011
Dosage : For adults, the recommended dose of brentuximab vedotin (recombinant) is 1.8mg/kg of body weight administered as an intravenous infusion every 3 weeks. Dose can be reduced based on symptoms by patients.
Common side effects of Adcetris include fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, fever, rash or itching, stomach or abdominal pain, cough, vomiting, tired feeling, constipation, weight loss, swelling in your hands or feet, dry skin, hair loss, headache, dizziness, anxiety, muscle spasm, muscle or joint pain, night sweats, sleep problems (insomnia), low white blood cell count or low blood platelet count (neutropenia or thrombocytopenia), or tingling or numbness in the hands and feet.